{"url_path":"/sec/avx/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1826397/0001493152-26-023348-index.html","accession_number":"0001493152-26-023348","cik":"0001826397","ticker":"AVX","issuer_name":"AVAX ONE TECHNOLOGY LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1826397/0001493152-26-023348-index.html","primary_entity_key":"0001826397","primary_entity_name":"AVAX ONE TECHNOLOGY LTD."},"word_count":87,"has_tables":true,"body_markdown":"**Item\n2. Unregistered Sales of Equity Securities and Use of Proceeds**\n\n \n\nOn January 2, 2026 and as part of the Company’s 2025 convertible debt facility, institutional investors purchased an additional tranche of $7,000,000 in convertible debentures with a 10% original\nissue discount for gross proceeds of $6,300,000 and received 3,013,245 warrants due January 2, 2027. The warrants are exercisable at\nany time and from time to time and expire July 2, 2029. The convertible debentures and warrants were issued with an exercise price of\n$2.41 per share."}